June 2022 

Discussion Topics:

• Presentation: “The Intersection between Spatial and Drug Discovery”, by Anna Lyubetskaya, Senior Principal Scientist, BMS 

• Spatial heterogeneity and the application of spatial technology to biomarkers 

• Advances in high-throughput ‘omics’ technologies to accelerate the pace of biomarker discovery 
• Comprehensive molecular profiling for improved diagnostics and therapeutics 
• Limitations of different omics platforms 

Discussion Leaders:

• Axel Ducret, Senior Principal Scientist, Roche
• Vilma Decman, Senior Scientific Director; Head of the Cellular Biomarkers, GSK
• Anna Lyubetskaya, Senior Principal Scientist, BMS

May 2022

Discussion Topics:

• Presentation: “Spatial Biology for Biomarker Discovery In Immuno-Oncology ” by Yu Liang, Director, Clinical Biomarker at Compugen 
• Limitations of predictive biomarkers in immuno-oncology
• Improving biomarker discovery with multiplex immunofluorescence 
• Application of spatial biomarkers in translational and clinical research 

Discussion Leaders:

• Yu Liang, Director, Clinical Biomarker, Compugen
• Rajit Kolammunne, Senior Scientist BioScience, AstraZeneca
• Vilma Decman, Senior Scientific Director; Head of the Cellular Biomarkers, GSK

April 2022

Discussion Topics:

• Presentation: “Fluid Biomarkers For Neurodegenerative Diseases“, by Jordi Clarimon, Head of Fluid Biomarkers, Lundbeck 
• Novel fluid biomarkers for neurodegenerative diseases development and diagnosis 
• Challenges of the field & how they could be overcome with new methodological advances 

Discussion Leader:

 Jordi Clarimon, Lead of Fluid Biomarkers, Lundbeck 

March 2022

Discussion Agenda:

• Presentation by Kathryn Newhall, VP of Translational Clinical Development, Cellectis
• Presentation by John Rossi, Head of Translational Medicine, SVP Research, Cero Therapeutics 
• Panel Discussion: Translation in the Clinic
  
  

Discussion Leaders: 

• Kathryn Newhall, VP of Translational Clinical Development, Cellectis 
• John Rossi, Head of Translational Medicine, SVP Research, Cero Therapeutics

February 2022

Discussion Topics: 

• How biomarkers may inform a meaningful clinical decision for a specific patient 
• Clinical, statistical and regulatory issues in the use of biomarkers as clinical endpoints 

Discussion Leader:

• Deepti Aurora-Garg, Executive Director Companion Diagnostics, Merck

December 2021

Flow cytometry is a powerful quantitative and preparative tool, allowing for the analytical interrogation of single cells amongst potentially millions of cells in minutes. Since its inception in 1953 and commercial popularisation in the 1970s, flow cytometry has emerged as a leading and sophisticated technology in applying the high-resolution characterisation of single cells within complex cellular networks. Challenges remain, however, and in our first biomarkers discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.

Discussion Points:

• Validating flow cytometry techniques 
• Developing high-throughput approaches & improving robustness 
• Data management strategies, including informatics, sample delivery & AI/ML approaches 
• Multiplexed high-throughput flow cytometry for drug discovery & repurposing 
• Regulatory perspectives on the various barriers/challenges of flow-based testing  

Discussion Group Leaders:

• Larry A. Sklar,
  Distinguished Professor Emeritus, University of New Mexico
• Maria Hernandez-Fuentes,
  Head of Huma Tissue Technologies, UCB